SEC Form 4 · accession 0001209191-16-136460
Axogen, Inc. · AXGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph M Mandato
Director
Period of report
Aug 8, 2016
Accepted (ET)
Aug 10, 2016 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000805928
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Aug 8, 2016 | S | 107,450 | $8.63 | D | 1,268,941 | I | By De Novo Ventures II, L.P. |
| Common StockF4,F3 | Aug 9, 2016 | S | 42,168 | $8.30 | D | 1,226,773 | I | By De Novo Ventures II, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.50 and $8.67 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2The Form 4 filed with the SEC on June 3, 2015 over reported the amount of securities beneficially owned following the reported transaction by one share, which has been corrected in this filing.
- F3The shares are owned by De Novo Ventures II, L.P. ("DNV II"). De Novo Management II, LLC is the sole general partner of DNV II. The reporting person is a managing member of De Novo Management II, LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F4Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $8.27 and $8.34 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.